Protection of Mice from Lethal Infection with Aujeszky's Disease Virus by Immunization with Purified gVI

Abstract

SUMMARYVirus envelope glycoprotein gVI (gp50) of Aujeszky's disease virus (ADV) was purified from a Nonidet P40-solubilized lysate of ADV-infected Vero cells by immunoaffinity chromatography using a monoclonal antibody against gVI. Mice immunized by the purified gVI produced virus-neutralizing antibody and were successfully protected against subsequent challenge with ADV.

Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine

“…Nevertheless, the conditions of challenge which were used seem to be less severe than ours, because only 80~ of the control mice died. To protect all mice against the same conditions of challenge as ours, Ishii et al (1988) needed to inject mice twice with 5 ~tg of purified gp50 emulsified in complete Freund's adjuvant. When two doses of 1 ~tg in adjuvant were used, protection of mice was comparable to that described here for group 3.…”

Effective priming of neonates born to immune dams against the immunogenic pseudorabies virus glycoprotein gD by replication-incompetent adenovirus-mediated gene transfer at birth.

“…gD is a major immunogen of PRV (Wathen & Wathen, 1984 ;Eloit et al, 1988 ;Coe & Mengeling, 1990). Vaccination of mice or pigs with purified or recombinant gD, or recombinant virus vectors, conferred protection to the animals (Eloit et al, 1990 ;Ganne et al, 1994 ;Ishii et al, 1988 ;Marchioli et al, 1987 ;Riviere et al, 1992). We compared the efficiency of replication-defective adenoviruses and genetic immunization in the priming of neonate piglets born to immune sows against gD.…”

Isogenic adenoviruses type 5 expressing or not expressing the E1A gene: efficiency as virus vectors in the vaccination of permissive and non-permissive species

“…To do so, similar viruses expressing the same gene [gD from pseudorabies virus (PRV) under the control of the major late promoter (MLP) from adenovirus type 2] were compared for in vitro growth properties and vaccine efficiency. The glycoprotein gD (formerly referred as gp50) is a strong immunogen of PRV, which is able to induce a protective immune response against challenge in several animal species (Marchioli et al, 1987;Eloit et al, 1988;Ishii et al, 1988). The defective virus (Ad-gD) was previously described (Eloit et al, 1990).…”